New aproach to periocular basal cell carcinoma treatment: Imiquimod;Nova modalidade no tratamento do carcinoma basocelular periocular: Imiquimode

Revista Brasileira de Oftalmologia

Volumn 66, Issue 6, 2007, Pages 411-417

  Santiago De Macedo, Erick Marcet ^a   Carneiro, Rachel Camargo ^a   Matayoshi, Suzana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antineoplastic agents therapeutic use; Carcinoma, basal cell drug therapy; Eyelid neoplasms pathology; Immunologic factors; Review literature

Indexed keywords

EID: 77949954684     PISSN: 00347280     EISSN: 19828551     Source Type: Journal    
DOI: 10.1590/s0034-72802007000600010     Document Type: Article

References (30)

1. Salomon J, Bieniek A, Baran E, Szepietowski JC. Basal cell carcinoma on the eyelids: own experience. Dermatol Surg. 2004;30(2 Pt 2):257-63.
2. Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112(4):717-23.
3. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327(7418):794-8. Review.
4. Ishi LA, Pereira IC, Schellini SA, Marques MEA, Padovani CR. Carcinoma basocelular da pálpebra: fatores relacionados com a recidiva tumoral. An Bras Dermatol. 2004;79(4):423-30.
5. Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2007; Mar. 8 [Epub ahead of print].
6. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722-33.
7. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939-47.
8. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003;139(10):1325-32.
9. Comment in: Arch Dermatol. 2003;139(10):1347-50.
10. Gupta AK, Browne M, Bluhm R. Imiquimod: a review. J Cutan Med Surg. 2002;6(6):554-60.
11. Blasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol. 2005;140(6):1136-9.
12. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol. 2003;139(10):1347-50.
13. Comment on: Arch Dermatol. 2003;139(10):1325-32.
14. Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg. 2005;31(3):318-23.
15. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 2001;44(3):462-70.
16. Roseeuw D. The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum. Clin Exp Dermatol. 2003; 28 Suppl 1: 30-2.
17. Leppälä J, Kaarniranta K, Uusitalo H, Kontkanen M. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand. 2007;85(5):566-8.
18. Schön MP, Schön M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis. 2004;9(3):291-8.
19. Mirza B, De'Ambrosis B. Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream. Clin Exp Dermatol. 2003; 28 Suppl 1: 16-8.
20. Sullivan T P, Dearaujo T, Vincek V, Berman B. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg. 2003;29(12):1181-6.
21. Ramdial PK, Madaree A, Reddy R, Chetty R. bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol. 2000;27(6):283-91.
22. Tilli CM, Stavast-Koey AJ, Ramaekers FC, Neumann HA. Bax expression and growth behavior of basal cell carcinomas. J Cutan Pathol. 2002;29(2):79-87.
23. Crowson AN, Magro CM, Kadin ME, Stranc M. Differential expression of the bcl-2 oncogene in human basal cell carcinoma. Hum Pathol. 1996;27(4):355-9.
24. Geisse JK, Rich P, Pandyá, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a doubleblind, randomized, vehicle-controlled study. J AM Acad Dermatol 2002; 47: 390-398.
25. Cousin F, Baldassini S, Bourchany D, Claudy A, Kanitakis J. Expression of the pro-apoptotic caspase 3/CPP32 in cutaneous basal and squamous cell carcinomas. J Cutan Pathol. 2000;27(5):235-41.
26. Berman B, Ricotti CA Jr, Cazzaniga A, Davis SC. Determination of the area of skin capable of being covered by the application of 250 mg of 5% imiquimod cream. Dermatol Surg. 2004;30(5):784-6.
27. Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165-71.
28. Aldara [text on the Internet]. Saint Paul: 3M Pharmaceuticals; 2004. [cited 2007 Mai 2]. Available from: http://www.fda.gov/medwatch/SAFETY/2004/mar- PI/Aldara-PI.pdf
29. Vidal D, Matías-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol. 2004;151(3):656-62.
30. Festa Neto C. Tratamento tópico do carcinoma basocelular superficial e nodular pelo imiquimod creme a 5%: observação de 10 casos. An Bras Dermatol. 2002;77(6):693-8.